Westermann Dirk, Schultheiss Heinz-Peter, Tschöpe Carsten
Department of Cardiology and Pneumology, Charité, University Medicine Berlin, Campus Benjamin Franklin, Berlin, Germany.
Int Immunopharmacol. 2008 Feb;8(2):148-54. doi: 10.1016/j.intimp.2007.07.022. Epub 2007 Aug 17.
An intensification of the local cardiac kallikrein-kinin system (KKS) is thought to delay the development of cardiac failure. Since myocardial infarction is one of the leading causes of death in the developed countries, the role of the kallikrein-kinin system was studied in numerous experimental studies focusing on this disease using strategies like kallikrein gene transfer, tissue kallikrein infusion and/or by use of human kallikrein over expressing animals. These studies suggested that the kallikrein-kinin system increases coronary blood flow, decreases infarct size and left ventricular remodeling post myocardial infarction. This is of special interest since pharmacological inhibition of the angiotensin converting enzyme acts not only by reducing angiotensin II levels, but also by preventing enzymatic breakdown of kinins, suggesting that the kallikrein-kinin system is part of ACE inhibition effects. Here we review the current concept of the kallikrein-kinin system during myocardial infarction with special regard to its effects on angiogenesis and myocardial regeneration.
局部心脏激肽释放酶 - 激肽系统(KKS)的强化被认为可延缓心力衰竭的发展。由于心肌梗死是发达国家主要的死亡原因之一,因此在众多针对该疾病的实验研究中,通过激肽释放酶基因转移、组织激肽释放酶输注和/或使用激肽释放酶过表达动物等策略,对激肽释放酶 - 激肽系统的作用进行了研究。这些研究表明,激肽释放酶 - 激肽系统可增加冠状动脉血流量,减小心肌梗死后的梗死面积并减轻左心室重构。这一点尤为重要,因为血管紧张素转换酶的药理抑制作用不仅通过降低血管紧张素II水平起作用,还通过防止激肽的酶促降解起作用,这表明激肽释放酶 - 激肽系统是ACE抑制作用的一部分。在此,我们回顾心肌梗死期间激肽释放酶 - 激肽系统的当前概念,特别关注其对血管生成和心肌再生的影响。